257 related articles for article (PubMed ID: 16968538)
1. Hemolytic uremic syndrome following the infusion of oxaliplatin: case report.
Dahabreh I; Tsoutsos G; Tseligas D; Janinis D
BMC Clin Pharmacol; 2006 Sep; 6():5. PubMed ID: 16968538
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.
Cobo F; De Celis G; Pereira A; Latorre X; Pujadas J; Albiol S
Anticancer Drugs; 2007 Sep; 18(8):973-6. PubMed ID: 17667605
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity reactions to oxaliplatin in two asian patients.
Ng CV
Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
[TBL] [Abstract][Full Text] [Related]
4. Hemolytic uremic syndrome induced by infusion of oxaliplatin: a case report.
Racca P; Spadi R; Fora G; Fanchini L; Ritorto G; Ferrari L; Pinta F; Lista P; Ciuffreda L
Tumori; 2011; 97(5):31e-3e. PubMed ID: 22158507
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin-induced immune pancytopenia.
Taleghani BM; Meyer O; Fontana S; Ahrens N; Novak U; Borner MM; Salama A
Transfusion; 2005 May; 45(5):704-8. PubMed ID: 15847658
[TBL] [Abstract][Full Text] [Related]
6. Management of allergic reactions to oxaliplatin in colorectal cancer patients.
Suenaga M; Mizunuma N; Shinozaki E; Matsusaka S; Chin K; Muto T; Konishi F; Hatake K
J Support Oncol; 2008; 6(8):373-8. PubMed ID: 19149322
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin hypersensitivity: case report and successful repeat desensitization.
Edmondson DA; Gruling BJ; Urmanski AM; Wong SJ; Levy MB
Am J Ther; 2007; 14(1):116-8. PubMed ID: 17303980
[TBL] [Abstract][Full Text] [Related]
8. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol.
Gammon D; Bhargava P; McCormick MJ
Oncologist; 2004; 9(5):546-9. PubMed ID: 15477639
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients.
Tonini G; Santini D; Vincenzi B; Borzomati D; Dicuonzo G; La Cesa A; Onori N; Coppola R
J Biol Regul Homeost Agents; 2002; 16(2):105-9. PubMed ID: 12144121
[TBL] [Abstract][Full Text] [Related]
10. Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event.
Wenzel C; Urbauer E; Schwarz C; Funk G; Oehler L; Kornek GV; Scheithauer W
Anticancer Drugs; 2006 Aug; 17(7):865-8. PubMed ID: 16926637
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
[TBL] [Abstract][Full Text] [Related]
12. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
Nozawa H; Muto Y; Yamada Y
Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
Fuse N; Doi T; Ohtsu A; Takeuchi S; Kojima T; Taku K; Tahara M; Muto M; Asaka M; Yoshida S
Jpn J Clin Oncol; 2007 Jun; 37(6):434-9. PubMed ID: 17656481
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report.
Buti S; Riccò M; Chiesa MD; Copercini B; Tomasello G; Brighenti M; Passalacqua R
Anticancer Drugs; 2007 Mar; 18(3):297-300. PubMed ID: 17264762
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
17. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
[TBL] [Abstract][Full Text] [Related]
18. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
19. Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?
Elligers KT; Davies M; Sanchis D; Ferencz T; Saif MW
JOP; 2008 Mar; 9(2):197-202. PubMed ID: 18326929
[TBL] [Abstract][Full Text] [Related]
20. Successful desensitization to oxaliplatin.
Mis L; Fernando NH; Hurwitz HI; Morse MA
Ann Pharmacother; 2005 May; 39(5):966-9. PubMed ID: 15784807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]